RxDoctor Payments Data

Myint Thway, MD

Rheumatology · Jacksonville, FLNPI 1568600575

Payments from drug & device makers

$2,593in general payments, 2019–2025

Across 111 payments — averaging $23.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$458
  • AbbVie$412
  • AstraZeneca$329
  • UCB, Inc.$261
  • Pfizer$246
  • E.r. Squibb & Sons, L.L.C.$186
  • plus $701 from 13 others
$1,328in research payments, 2019–2025

Across 7 payments — averaging $189.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$1K

What the payments were for

  • Travel & lodging$1867%
  • Food & beverage$2,38792%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,593 in reported general payments places this provider in the 30th percentile of 453 rheumatology providers in Florida.

See all rheumatology providers in Florida

Medicare billing

Part B allowed, 2024
$95,357
Medicare patients
235
Services billed
2,309

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab105$722,772
EnbrelEtanercept42$282,930
Orencia ClickjectAbatacept37$230,488
Enbrel SureclickEtanercept21$170,332
Cosentyx Sensoready (2 Pens)Secukinumab21$167,659
OtezlaApremilast24$116,491
XeljanzTofacitinib Citrate12$69,485
Hydroxychloroquine Sulfate352$13,240
RasuvoMethotrexate/Pf21$11,878
Leflunomide82$6,571
MethotrexateMethotrexate Sodium234$6,158
Mycophenolate Mofetil43$6,051
Colchicine37$3,583
Diclofenac Sodium46$2,650
Dapsone18$1,475

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel, Otezla$178$399,42266 claims
PfizerXeljanz$246$69,48512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 453 rheumatology providers in Florida.

Other rheumatology in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →